18 patents
Utility
Agitation process for preparing a carbetocin drug product
19 Dec 23
The present disclosure includes a method of making an improved carbetocin drug product.
Christopher Bryant, Mark C. Manning, Ryan E. Holcomb
Filed: 2 Mar 22
Utility
Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
12 Dec 23
Marlon Carlos, Sagun Tandel, Roger Olsson, Mikael Hillgren, Matthew J. Fleming, Andreas Philipp Boudier, Beat T. Weber
Filed: 16 Mar 21
Utility
Crystalline forms of trofinetide
28 Nov 23
This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.
Matthew Peterson, Marlon Carlos, Martin Bernard Catherine Bousmanne, Cecilia Betti, David T. Jonaitis, Lisa M. McCracken, Lisa M. Grove
Filed: 12 Jul 22
Utility
Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
11 Oct 22
Methods for the treatment of Alzheimer's disease psychosis, or a symptom thereof, comprising administering pimavanserin.
Bruce Duane Coate, James Randall Owen, Mark Donald Knowles, Srdjan R. Stankovic, James M. Youakim
Filed: 14 Dec 17
Utility
Formulations of pimavanserin
27 Sep 22
Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.
Ravindra Tejwani, Stephen Edward Abele, Emanuel Joseph Vizzotti
Filed: 14 Mar 22
Utility
Compounds, salts thereof and methods for treatment of diseases
13 Sep 22
The present disclosure relates to compounds according to Formulae (I), (II) and (VIII), useful for treating diseases.
Ethan S. Burstein, Roger Olsson, Karl Erik Jansson, Niklas Patrik Sköld, Larisa Yudina Wahlström, Björn Gustav Borgström, Henrik Von Wachenfeldt, Magnus Gustav Wilhelm Bergner
Filed: 20 Aug 18
Utility
Compounds, salts thereof and methods for treatment of diseases
31 May 22
The present disclosure relates to compounds according to Formula (I), useful for treating diseases.
Ethan S. Burstein, Roger Olsson, Björn Gustav Borgström, Karl Erik Jansson, Niklas Patrik Sköld, Henrik Von Wachenfeldt, Larisa Yudina Wahlström
Filed: 21 Feb 20
Utility
Combination of pimavanserin and cytochrome P450 modulators
7 Dec 21
A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.
Andrew Parkinson
Filed: 15 Nov 19
Utility
Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent
2 Nov 21
Provided herein are methods of making a thiazoline anti-hyperalgesic, Compound 1, and polymorphs thereof.
Scott L. Dax
Filed: 10 Mar 20
Utility
Pimavanserin for treating impulse control disorder
5 Oct 21
A method for treating a impulse control disorder in a patient comprising administering to the patient an effective amount of pimavanserin or a pharmaceutical acceptable salt thereof.
Ethan S. Burstein
Filed: 27 Apr 18
Utility
Compounds for pain treatment, compositions comprising same, and methods of using same
17 Aug 21
The invention relates to compounds of formula (I), compositions containing the same, and methods for treating and/or diminishing pain in a subject in need thereof.
Scott L. Dax, Pasquale N. Confalone
Filed: 20 May 19
Utility
Combination of pimavanserin and cytochrome P450 modulators
23 Mar 21
A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.
Andrew Parkinson
Filed: 23 Mar 17
Utility
Formulations of pimavanserin
30 Nov 20
Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.
Ravi Tejwani, Stephen Edward Abele, Emanuel Joseph Vizzotti
Filed: 30 Mar 20
Utility
Formulations of pimavanserin
11 May 20
Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.
Ravi Tejwani, Stephen Edward Abele, Emanuel Joseph Vizzotti
Filed: 15 Sep 19
Utility
Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C
23 Mar 20
Marlon Carlos, Sagun Tandel, Roger Olsson, Mikael Hillgren, Matthew J. Fleming, Andreas Philipp Boudier, Beat T. Weber
Filed: 18 Jul 16
Utility
Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
6 Jan 20
Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias.
David M. Weiner, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam
Filed: 25 Jun 18
Utility
Combination of pimavanserin and cytochrome P450 modulators
30 Dec 19
A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.
Andrew Parkinson
Filed: 8 Apr 19
Utility
Formulations of pimavanserin
21 Oct 19
Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.
Ravi Tejwani, Stephen Edward Abele, Emanuel Joseph Vizzotti
Filed: 24 Mar 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first